Literature DB >> 3258330

Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity.

E Cornacchia1, J Golbus, J Maybaum, J Strahler, S Hanash, B Richardson.   

Abstract

Inhibitors of DNA methylation, such as 5-azacytidine, induce gene expression. We have previously reported that cloned T cells treated with 5-azacytidine lose the requirement for Ag and can be activated by autologous HLA-D molecules alone, thus becoming auto-reactive. This phenomenon could potentially mediate an autoimmune disease in vivo. Inasmuch as several drugs are known to cause autoimmune disease, we asked whether they exert the same effects on T cells as 5-azacytidine. We report that hydralazine and procainamide, two drugs associated with a lupus-like autoimmune disease, also inhibit DNA methylation and induce self-reactivity in cloned T cell lines. These results suggest that drug-induced autoimmune disease may be due to activation of as yet unidentified genes through mechanisms involving DNA methylation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258330

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  118 in total

1.  Analysis of human peripheral blood T cells and single-cell-derived T cell clones uncovers extensive clonal CpG island methylation heterogeneity throughout the genome.

Authors:  X Zhu; C Deng; R Kuick; R Yung; B Lamb; J V Neel; B Richardson; S Hanash
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 2.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 3.  Using Epigenetic Therapy to Overcome Chemotherapy Resistance.

Authors:  Julius Strauss; William D Figg
Journal:  Anticancer Res       Date:  2016-01       Impact factor: 2.480

Review 4.  Drug-related lupus. Incidence, mechanisms and clinical implications.

Authors:  L E Adams; E V Hess
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 5.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

Review 6.  Clinical applications of epigenetics in cardiovascular disease: the long road ahead.

Authors:  Stella Aslibekyan; Steven A Claas; Donna K Arnett
Journal:  Transl Res       Date:  2014-04-08       Impact factor: 7.012

Review 7.  DNA methylation alterations in the pathogenesis of lupus.

Authors:  S H Chen; Q L Lv; L Hu; M J Peng; G H Wang; B Sun
Journal:  Clin Exp Immunol       Date:  2016-11-01       Impact factor: 4.330

8.  Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice.

Authors:  J Quddus; K J Johnson; J Gavalchin; E P Amento; C E Chrisp; R L Yung; B C Richardson
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

Review 9.  Key role of ERK pathway signaling in lupus.

Authors:  Gabriela Gorelik; Bruce Richardson
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

10.  CD3Z hypermethylation is associated with severe clinical manifestations in systemic lupus erythematosus and reduces CD3ζ-chain expression in T cells.

Authors:  Kyeong-Man Hong; Hyun-Kyoung Kim; Seong-Yeol Park; Shiv Poojan; Mi-Kyung Kim; Joohon Sung; Betty P Tsao; Jennifer M Grossman; Ornella J Rullo; Jennifer M P Woo; Deborah K McCurdy; Lisa G Rider; Frederick W Miller; Yeong-Wook Song
Journal:  Rheumatology (Oxford)       Date:  2017-03-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.